Search

Your search keyword '"Langerød A"' showing total 81 results

Search Constraints

Start Over You searched for: Author "Langerød A" Remove constraint Author: "Langerød A" Database Unpaywall Remove constraint Database: Unpaywall
81 results on '"Langerød A"'

Search Results

1. Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer—a prospective national multicentre study (EMIT-1)

2. 103P Impact of Prosigna test on treatment decision in lymph node-negative early breast cancer: A prospective multicenter study (EMIT1)

3. Supplementary Figures S1-S5, Tables 1-3 from Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53

4. Supplementary Figures S1-S5, Tables 1-3 from Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53

5. Supplementary figures from Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice

6. Supplementary Figure 7 from TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

7. Supplementary Tables from The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer

8. Data from Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice

9. Supplementary Figure 2 from TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

10. Data from Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice

11. Supplementary Figure 6 from TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

12. Supplementary Figure 4 from TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

13. Supplementary Figure 5 from TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

14. Supplementary Figure 3 from TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

15. Supplementary Figure 8 from TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

16. Supplementary Figure Legends from TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

17. Supplementary figures from Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice

18. Supplementary Figure 1 from TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

20. Comparing 5-Year Survival Rates Before and After Re-stratification of Stage I–III Right-Sided Colon Cancer Patients by Establishing the Presence/Absence of Occult Tumor Cells and Lymph Node Metastases in the Different Levels of Surgical Dissection

26. Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences

27. The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer

28. Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice

31. Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration

32. Direct Transcriptional Consequences of Somatic Mutation in Breast Cancer

33. Landscape of somatic mutations in 560 breast cancer whole-genome sequences

34. The Sub-Cellular Localization of WRAP53 Has Prognostic Impact in Breast Cancer

35. The Life History of 21 Breast Cancers

36. Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53

37. Abstract PR06: Lymphocyte invasion of basal breast tumors is associated with wild-type p53

39. TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

40. AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53

42. Mutational Processes Molding the Genomes of 21 Breast Cancers

43. The Life History of 21 Breast Cancers

45. Functional characterization of the 19q12 amplicon in grade III breast cancers

46. Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway

49. Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters

Catalog

Books, media, physical & digital resources